#
Arcapta Neohaler
  • Treatments
  • COPD
  • Maintenance
  • Arcapta Neohaler (Inhalation)

Arcapta Neohaler (Inhalation)

Generic name:indacaterol (inhalation route) [ in-da-KAT-er-ol ]
Drug class:Adrenergic bronchodilators

Medically reviewed by Drugs.com. Last updated on Feb 19, 2022.

Commonly used brand name(s)

In the U.S.

  • Arcapta Neohaler

Available Dosage Forms:

  • Capsule

Therapeutic Class: Bronchodilator

Pharmacologic Class: Beta-2 Adrenergic Agonist

Uses for Arcapta Neohaler

Indacaterol is used for the long-term maintenance treatment of air flow blockage in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. COPD is a long-term lung disease that causes bronchospasm (wheezing or difficulty with breathing).

Indacaterol is a long-acting bronchodilator. Bronchodilators are medicines that are breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. They relieve cough, wheezing, shortness of breath, and troubled breathing by increasing the flow of air through the bronchial tubes.

This medicine is available only with your doctor's prescription.

Before using Arcapta Neohaler

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Indacaterol is not indicated for use in the pediatric population. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of indacaterol in the elderly.

Breastfeeding

There are no adequate studies in women for determining inf...